Stock Yards Bank & Trust Co. Sells 9,233 Shares of Danaher Corporation $DHR

Key Points

• Stock Yards Bank & Trust Co. has decreased its stake in Danaher Corporation by 17.9% during the 2nd quarter, now holding 42,301 shares valued at approximately $8.36 million.
• Analysts' ratings for Danaher vary, with several upgrades resulting in a consensus of "Moderate Buy" and an average price target of $245.91.
• Danaher recently announced a quarterly dividend of $0.32, representing an annualized yield of 0.6%, to be paid to stockholders on October 31st.

Stock Yards Bank & Trust Co. decreased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 17.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,301 shares of the conglomerate's stock after selling 9,233 shares during the period. Stock Yards Bank & Trust Co.'s holdings in Danaher were worth $8,356,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. MGO One Seven LLC lifted its stake in Danaher by 485.7% in the 1st quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock valued at $5,145,000 after purchasing an additional 20,813 shares during the last quarter. Chicago Capital LLC lifted its stake in Danaher by 11.6% in the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate's stock valued at $2,634,000 after purchasing an additional 1,391 shares during the last quarter. UniSuper Management Pty Ltd lifted its stake in Danaher by 1.6% in the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock valued at $34,954,000 after purchasing an additional 2,667 shares during the last quarter. Asahi Life Asset Management CO. LTD. acquired a new stake in Danaher in the 1st quarter valued at about $539,000. Finally, Horizon Financial Services LLC lifted its stake in Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after purchasing an additional 8,160 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on DHR shares. Weiss Ratings reiterated a "hold (c-)" rating on shares of Danaher in a research note on Saturday, September 27th. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. UBS Group cut their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Finally, Bank of America cut their price objective on shares of Danaher from $230.00 to $220.00 and set a "buy" rating for the company in a research report on Monday, September 22nd. Seventeen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $245.91.

Danaher Stock Up 2.2%

NYSE DHR opened at $215.05 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.41. The company has a 50 day moving average of $200.19 and a 200-day moving average of $197.42. The company has a market cap of $153.98 billion, a price-to-earnings ratio of 45.75, a PEG ratio of 3.00 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the business earned $1.72 earnings per share. The firm's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's payout ratio is presently 27.23%.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.